A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
The purpose of this study is to see if combination treatment of T-DM1 with palbociclib is better than T-DM1 alone for metastatic HER2-positive breast cancer.
Metastatic HER2-positive Breast Cancer
Male of female 18 years or older
Recurrent or metastatic HER2-positive breast cancer
Previously treated with pertuzumab (neoadjuvant or metastatic setting)
No more than 2 lines of therapy in the metastatic disease setting
18 - 101
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug for as long as your cancer does not get worse or you do not have bad side effects. After you finish study drug the investigator and/or study team will continue to watch you for side effects and follow your condition either with clinic visits or phone calls. This follow-up period will last until study completion.
Knight Clinical Trials Information Line
The University of Arizona Cancer Center